blavity.com /1 week ago

Targeted Therapy Sac-TMT Could Change The Future Of Endometrial Cancer Treatment

For people whose endometrial cancer returns after treatment, finding another effective option can be difficult.

Read source
aacr.org /1 month ago

HER2-targeted Therapy for Salivary Gland Cancer

Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...

Read source
nytimes.com /1 month ago

New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?

Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.

Read source
bioengineer.org /1 week ago

Meta-Analysis Assesses Targeted Therapies for MET-Altered Non-Small Cell Lung Cancer

A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective response rate in MET-altered non-small cell lu...

Read source
aacr.org /2 weeks ago

Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53

The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cance...

Read source
genengnews.com /1 week ago

Therapeutic Immune Manipulation

Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces. The post Therapeutic Immune Manipulation appeared first o...

Read source
genengnews.com /3 days ago

Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice

Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse...

Read source
biopharmadive.com /5 days ago

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
aacr.org /1 month ago

A New Way In: How Outside-the-box Science Sparked a Revolution in Targeting KRAS

At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize for his pioneering discoveries that opened the door to th...

Read source
bioengineer.org /1 month ago

Oral Wnt-blocking pill plus lenvatinib shows promise in endometrial cancer after immunotherapy fails

An experimental oral cancer drug that disrupts a key molecular switch inside tumour cells, when paired with an established targeted therapy, has produced durable tumour shrinkage i...

Read source
biopharmadive.com /2 weeks ago

T-Therapeutics reloads with a $133M megaround for bispecifics

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.

Read source
biopharmadive.com /2 weeks ago

At ASH, drugmakers to showcase early data for three-pronged cancer therapies

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.

Read source
bioengineer.org /1 month ago

mRNA Vaccine Paired With Radiotherapy Shrinks HER2-Positive Lung Tumors in Mice

A HER2-targeted mRNA lipid nanoparticle vaccine combined with fractionated radiotherapy suppressed tumor growth and reprogrammed the immune microenvironment in a mouse model of HER...

Read source
qchron.com /1 week ago

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FD...

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...

Read source
pharmexec.com /2 weeks ago

<![CDATA[How Changes in a Tumor Have a Significant Impact on Treatment Options]]>

Read source
bioengineer.org /1 week ago

Immunotherapy Combined With Chemotherapy Extends Survival in Advanced SMARCA4-Deficient Lung Cancer

A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...

Read source
qchron.com /3 weeks ago

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy

Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C Therapy

Read source
cassling.com /3 weeks ago

Building a Scalable Theranostics Program: Five Lessons from Nebraska Cancer Specialists

Theranostics, also called radiotheranostics, combines targeted disease diagnosis and therapy into an integrated medical process for oncology providers. Although the field isn’t new...

Read source
qchron.com /2 weeks ago

Creative Biogene Launches Lentiviral Vector-Based In Vivo CAR-T Development to Pioneer the Future of Cancer Therapy

Creative Biogene proudly announces the launch of its flagship lentiviral vector-based in vivo CAR-T development services, aimed at revolutionizing cancer treatments through precisi...

Read source
qchron.com /4 weeks ago

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Ca...

GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...

Read source
seekingalpha.com /6 days ago

Ideaya picks cancer drug candidate, targets human trial application in 2027

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Me...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.